GlobeImmune and partner Gilead suffered a setback this week after its new hepatitis B vaccine GS-4774 missed its mid-stage trial target.
News
UK government commits to health spend increases
The UK government will increase its healthcare spending in England by at least £8 billion a year by 2020 and make the NHS a seven-day a week service.
Bayer plans corporate restructure
Bayer is developing plans to overhaul its corporate structure to more closely align its two life sciences businesses, but says the move will not see any staff reductions.
Eight new medicines recommended by CHMP
Eight new medicines have been recommended for approval by the European Medicines Agency with three new cancer biologics also gaining the nod.
NHS Trusts’ funding gap rises to nearly £1bn
NHS Trusts in England have seen their deficits grow to an eye-watering £822 million in 2014-15, compared with just £115 million the previous year.
Sanofi’s Jevtana given last-minute CDF reprieve
Sanofi has reached an eleventh hour reprieve with NHS England that will see its advanced prostate cancer drug Jevtana (cabazitaxel) once more become available on the NHS.
Bayer’s Stivarga wins appeal to stay on CDF
Bayer’s Stivarga (regorafenib) will remain on England’s Cancer Drugs Fund as a treatment for gastrointestinal stromal tumours following an appeal against NHS England’s decision earlier this year to remove it from the list.
BMA slams seven-day GP services ‘obsession’
The government must halt its obsession with seven-day GP practices and act on the funding and recruitment crisis that is “a hurricane threatening to undermine the fabric of the NHS,” GP leaders have warned.
Alnylam gains on US orphan status for amyloidosis drug
Shares in Alnylam were on the rise after it emerged that its Genzyme-partnered amyloidosis RNAi therapeutic revusiran has been granted Orphan drug status in the US.
Boehringer, Eureka in intra-cellular antibodies pact
Boehringer Ingelheim and Eureka Therapeutics have signed a research deal to discover novel therapeutic antibodies in oncology.
Could you be the PharmaTimes Marketer of the Year 2015?
Entries are open for the PharmaTimes Marketer of the Year Awards, and the competition is set to be fierce…
Novartis’ Afinitor extends progression-free survival in NET
Novartis says late-stage clinical data show that its cancer drug Afinitor extended progression-free survival in patients with advanced nonfunctional neuroendocrine tumours (NET) of gastrointestinal or lung origin.
Novartis COPD therapies hit Phase III targets
A first look at data from pivotal Phase III trials assessing Novartis’ chronic obstructive pulmonary disorder medicines QVA149 and NVA237 show improvements across lung function and quality of life measures.
Regeneron/Sanofi drug improves RA symptoms in PhIII trial
Top-line data from a Phase III trial of Regeneron/Sanofi’s fully human monoclonal antibody sarilumab show that the drug significantly improved signs and symptoms of rheumatoid arthritis compared to placebo.
Astellas’ clostridium antibiotic Dificlir cut recurrence, costs
Real-world data on Astellas’ Dificlir has shown that the narrow-spectrum antibiotic significantly reduces recurrence and all-cause mortality when used first-line in all patients with Clostridium difficile infection.
